Marjon Pasmooij

PhD opportunity in regulatory science , rare diseases , leukodystrophies , and access to innovative therapies within the European Marie Skłodowska-Curie POLARIS Doctoral Network . The project will examine regulatory and access pathways for innovative therapies for leukodystrophies and other rare diseases. Research themes mentioned in the post include: facilitating the development of orphan medicines in academic settings, small-scale (“n-of-few”) manufacturing and quality control of ATMPs , identifying relevant patient-reported outcomes for leukodystrophy therapies, and improving cross-border access and reimbursement for innovative therapies in Europe. The PhD candidate will be based in the Science Department of the Dutch Medicines Evaluation Board (CBG-MEB) in Utrecht , working closely with partners at Amsterdam UMC and across the international POLARIS network. The post highlights an interdisciplinary environment spanning science, regulation, policy, and patient perspectives. Funding: This is a doctoral network PhD opportunity under MSCA POLARIS. The post does not specify stipend, tuition, or other financial details. Eligibility/requirements: No detailed entry requirements are listed in the post. The announcement emphasizes interest in rare diseases, regulatory science, access, policy, and patient-centered research. Deadline: 5 October 2026. How to apply: Follow the application link for the full call and submission instructions. Interested candidates are encouraged to review the opportunity promptly and apply before the deadline.